Elsevier

Surgery

Volume 117, Issue 1, January 1995, Pages 56-61
Surgery

Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells1

https://doi.org/10.1016/S0039-6060(05)80230-2Get rights and content

Background. Gallium nitrate and the bisphosphonates pamidronate and its dimethylated derivative comprise antihypercalcemic drugs with actions on bone. This study examines the in vitro effects of these compounds on human parathyroid cells.

Methods. Parathyroid hormone (PTH) release and the concentration of cytoplasmic calcium ion (Ca2+) of dispersed cells from parathyroid glands of 27 patients with sporadic primary or uremic hyperparathyroidism was measured.

Results. In 1.25 mmol/L external Ca2+, 200 μmol/L gallium nitrate inhibited PTH release from reparations of primary and uremic hyperparathyroidism by 14% and 22%, respectively. Similar reductions were evident also in 0.5 and 3.0 mmol/L Ca2+. The gallium nitrate-induced suppression of PTH release was dose dependent in the 2 to 200 μmol/L range. Cytoplasmic Ca2+ concentration displayed a biphasic rise on elevation of external Ca2+ and remained unaffected by gallium nitrate. None of the bisphosphonates altered PTH release of pathologic human or normal bovine parathyroid cells.

Conclusions. The results support clinical usefulness of gallium nitrate through its dual actions on bone and the parathyroid. The findings substantiate that gallium may reduce PTH release by stabilization of the plasma membrane rather than by interference with the surface cation receptor mediating Ca2+ regulation of the secretion.

References (45)

  • LarssonR et al.

    Dual effects of a new hypocalcemic agent, WR-2721, on cytoplasmic Ca2+ and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism

    Biochem Pharmacol

    (1986)
  • MalletteLE et al.

    Malignancy hypercalcemia: evaluation of parathyroid function and response to treatment

    Am J Med Sci

    (1991)
  • FraserWD et al.

    Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy

    Bone Miner

    (1991)
  • WarrellRP et al.

    Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia

    J Clin Invest

    (1984)
  • WarrellRP et al.

    Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis

    Cancer Res

    (1986)
  • WarrellRP et al.

    Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma

    Ann Intern Med

    (1987)
  • WarrellRP et al.

    Gallium nitrate for advanced Paget's disease of bone: effectiveness and dose-response analysis

    Ann Intern Med

    (1990)
  • BockmanRS et al.

    Gallium increases bone calcium and crystallite perfection of hydroxyapatite

    Calcif Tissue Int

    (1986)
  • WarrellRP et al.

    Gallium nitrate for malignant osteolysis: in vitro and clinical effects on parathyroid hormone

    Clin Res

    (1987)
  • RusselRGG et al.

    Pyrophosphate and diphosphonates in skeletal metabolism

    Clin Orthop

    (1975)
  • BijvoetOLM

    A pharmacological background for the use of APD in cancer

  • MarshallMJ et al.

    Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts

    J Bone Miner Res

    (1990)
  • Cited by (7)

    • The response of pre-osteoblasts and osteoclasts to gallium containing mesoporous bioactive glasses

      2018, Acta Biomaterialia
      Citation Excerpt :

      One of the most interesting therapeutic ions in the field of bone pathologies is Ga (III). The inhibition of bone resorption driven by Ga (III) has been widely reported [31–35]. Ga reduces the resorption activity, differentiation and formation of osteoclasts without cytotoxic effects in a dose-dependent manner, pointing out an excellent potential for the treatment of osteoporotic bone fractures associated to bone implants [36,37].

    • Hypercalcemia

      2015, Textbook of Palliative Medicine and Supportive Care
    • Milk alkali syndrome

      2002, Ulster Medical Journal
    • Treatment of malignant hypercalcaemia

      2002, Expert Opinion on Pharmacotherapy
    View all citing articles on Scopus
    1

    Supported by the Swedish Medical Research Council; Förenade Liv Mutual Group Life Insurance Co., Stockholm; and the Swedish Society of Medicine.

    View full text